A phase 2 study of amivantamab plus lazertinib in patients with EGFR-mutant lung cancer and active central nervous system disease Meeting Abstract
| Authors: | Yu, H. A.; Chen, M. F.; Hui, A. B.; Choudhury, N. J.; Lee, J. J. K.; Zheng, J.; Ahn, L. S. H.; Pupo, A.; Nesselbush, M.; Jabara, I.; Heller, G.; Arbour, K. C.; Santini, F. C.; Offin, M.; Chaft, J. E.; Young, R. J.; Riely, G. J.; Kris, M. G.; Diehn, M.; Boire, A. A. |
| Abstract Title: | A phase 2 study of amivantamab plus lazertinib in patients with EGFR-mutant lung cancer and active central nervous system disease |
| Meeting Title: | 2024 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2024 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-06-01 |
| Language: | English |
| ACCESSION: | WOS:001275557402015 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2024.42.16_suppl.8517 |
| Notes: | Meeting Abstract: 8517 -- Source: Wos |
